Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden

Health Policy

Volumn 104, Issue 1, 2012, Pages 84-91

  Pettersson, Billie ^a   Hoffmann, Mikael ^b   Wändell, Per ^c   Levin, Lars Åke ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Network for Pharmacoepidemiology Foundation   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Drug utilization; Health economics; Health technology assessment; Lipid modifying therapies; Pricing and reimbursement policy

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; LAROPIPRANT; LAROPIPRANT PLUS NICOTINIC ACID; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG COST; DRUG MEGADOSE; DRUG UTILIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRESCRIPTION; QUASI EXPERIMENTAL STUDY; REGRESSION ANALYSIS; REIMBURSEMENT; SWEDEN; TREND STUDY;

DRUG UTILIZATION REVIEW; ECONOMICS, PHARMACEUTICAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; LINEAR MODELS; REIMBURSEMENT MECHANISMS; SWEDEN; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 83555163959     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2011.10.010     Document Type: Article

References (42)

1. Greenland P., Knoll M.D., Stamler J., Neaton J.D., Dyer A.R., Garside D.B., et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. The Journal of the American Medical Association 2003, 290:891-897.
2. Khot U.N., Khot M.B., Bajzer C.T., Sapp S.K., Ohman E.M., Brener S.J., et al. Prevalence of conventional risk factors in patients with coronary heart disease. The Journal of the American Medical Association 2003, 290:898-904.
3. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
4. National Institute for Health and Clinical Excellence Statins for the prevention of cardiovascular events in patients at increased risk of developing cardiovascular disease or those with established cardiovascular disease 2006, http://www.nice.org.uk/TA094.
5. Medical Products and Agency Prevention av aterosklerotisk hjärtkärlsjukdom med lipidreglerande läkemedel 2005, http://www.lakemedelsverket.se/malgrupp/Halso---sjukvard/Behandlings--rekommendationer/Behandlingsrekommendation---listan/Hyperlipidemi/.
6. National Board of Health and Welfare Nationella riktlinjer för hjärtsjukvård. Tabellbilaga till beslutsstödsdokument - tillstånds- och åtgärdslistor för hjärtsjukdomar 2008, http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/8592/2008-102-7_20081027_bilaga_1.pdf.
7. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
8. Mills E.J., Wu P., Chong G., Ghement I., Singh S., Akl E.A., et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. Quarterly Journal of Medicine 2011, 104:109-124.
9. Richards M. Extent and causes of international variations in drug usage 2010, CBE, London.
10. Walley T., Folino-Gallo P., Schwabe U., van Ganse E. Variations and increase in use of statins across Europe: data from administrative databases. British Medical Journal (Clinical Research Ed.) 2004, 328:385-386.
11. The National Board of Health and Welfare The Swedish drug registry 2011, http://www.socialstyrelsen.se/register/halsodataregister/lakemedelsregistret.
12. Godman B., Shrank W., Wettermark B., Andersen M., Bishop I., Burkhardt T., et al. Use of generics - a critical cost containment measure for all healthcare professionals in Europe?. Pharmaceuticals 2010, 3:2470-2494.
13. The Dental and Pharmaceutical Benefits Agency (TLV) The review of medicines for treating lipid disorders 2009, http://www.tlv.se/Upload/Genomgangen/review-lipid-disorder.pdf.
14. Sakshaug S., Furu K., Karlstad O., Ronning M., Skurtveit S. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. British Journal of Clinical Pharmacology 2007, 64:476-481.
15. Martikainen J.E., Saastamoinen L.K., Korhonen M.J., Enlund H., Helin-Salmivaara A. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Medical Care 2010, 48:761-766.
16. Kalo Z., Muszbek N., Bodrogi J., Bidlo J. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy 2007, 80:402-412.
17. Winkelmayer W.C., Asslaber M., Bucsics A., Burkhardt T., Schautzer A., Wieninger P., et al. Impact of reimbursement changes on statin use among patients with diabetes in Austria. Wiener klinische Wochenschrift 2010, 122:89-94.
18. Stargardt T. The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany. The European Journal of Health Economics 2010, 11:267-277.
19. Ostini R., Hegney D., Jackson C., Williamson M., Mackson J.M., Gurman K., et al. Systematic review of interventions to improve prescribing. The Annals of Pharmacotherapy 2009, 43:502-513.
20. Godman B., Shrank W., Andersen M., Berg C., Bishop I., Burkhardt T., et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Review of Pharmacoeconomics & Outcomes Research 2010, 10:707-722.
21. Giuliani G., Selke G., Garattini L. The German experience in reference pricing. Health Policy 1998, 44:73-85.
22. Sjögren E. Reasonable drugs - making decisions with ambiguous knowledge 2006, The Economic Research Institute, Stockholm School of Economics, Stockholm.
23. Wettermark B., Godman B., Andersson K., Gustafsson L.L., Haycox A., Bertele V. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. PharmacoEconomics 2008, 26:537-550.
24. Polain M., Franken M., Koopmanshap M., Cleemput I. Drug reimbursement systems: international comparison and policy recommendations. KCE reports 147C 2010, Belgian Health Care Knowledge Centre, Brussels.
25. The Dental and Pharmaceutical Benefits Agency, TLV The pharmaceutical review 2011, http://www.tlv.se/in-english-old/in-english/.
26. Wettermark B., Godman B., Neovius M., Hedberg N., Mellgren T.O., Kahan T. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 2010, 94:221-229.
27. Decision 1699/2007; 2009, http://www.tlv.se/Upload/Beslut_2009/bes090211-zocord.pdf.
28. Grimshaw J., Campbell M., Eccles M., Steen N. Experimental and quasi-experimental designs for evaluating guideline implementation strategies. Family practice 2000, 17(Suppl. 1):S11-S16.
29. Wagner A.K., Soumerai S.B., Zhang F., Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. Journal of Clinical Pharmacy and Therapeutics 2002, 27:299-309.
30. Wettermark B., Hammar N., Fored C.M., Leimanis A., Otterblad Olausson P., Bergman U., et al. The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiology and Drug Safety 2007, 16:726-735.
31. Furu K., Wettermark B., Andersen M., Martikainen F, Almarsdottir A.B., Sorensen H.T. The Nordic countries as a cohort for pharmacoepidemiological research. Basic & Clinical Pharmacology & Toxicology 2009, 106:86-94.
32. Guidelines for ATC classification and DDD assignment 2010 2009, WHO Collaborating Centre for Drug Statistics Methodology, Oslo.
33. Wettermark B., Godman B., Jacobsson B., Haaijer-Ruskamp F.M. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Applied Health Economics and Health Policy 2009, 7:137-147.
34. Godman B., Wettermark B., Hoffmann M., Andersson K., Haycox A., Gustafsson L.L. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Review of Pharmacoeconomics & Outcomes Research 2009, 9:65-83.
35. Godman B., Sakshaug S., Berg C., Wettermark B., Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Review of Pharmacoeconomics & Outcomes Research 2011, 11:121-129.
36. Läkemedelsförmånsnämnden Rosuvastatin reimbursement decision 2003, http://www.tlv.se/Upload/Beslut/BES_030625_Crestor.pdf.
37. Karolinska Institutet Ongoing projects at Centre for Pharmacoepidemiology, Karolinska Institutet, Sweden, November 2010 2010, http://www.nhv.se/upload/dokument/forskning/N%C3%A4tverk/NorPEN/Ongoing%20projekt%20NorPEN.pdf.
38. Escobar C., Echarri R., Barrios V. Relative safety profiles of high dose statin regimens. Vascular Health and Risk Management 2008, 4:525-533.
39. Atar D., Carmena R., Clemmensen P.A., Wassmann K.L., Lansberg S., Hobbs P.R. Clinical review: impact of statin substitution policies on patient outcomes. Annals of Medicine 2009, 41:242-256.
40. Stafford R.S., Radley D.C. The potential of pill splitting to achieve cost savings - in reply. American Journal of Managed Care 2002, 8:925-926.
41. Hjemdahl P., Allhammar A., Heaton C., Hulting J., Kahan T., Malmstrom R., et al. SBU should investigate what is an evidence-based and cost-effective use of statins. Lakartidningen 2009, 106:1992-1994.
42. Polit D., Tatano Beck C. Nursing research: generating and assessing evidence for nursing practice 2008, Lippincott Williams & Wilkins, Philadelphia.